NCT00202891撤回4 期
Sisomicin Cream Vs Nadifloxacin Cream in Primary Pyodermas
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 撤回
研究概览
简要总结
This open-label, randomized, parallel-group clinical study is designed to compare the efficacy and safety of the topical antibiotic, sisomicin cream, with that of another topical antibiotic cream, nadifloxacin cream, in the treatment of Indian patients with primary pyodermas.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 6 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients of either sex and suffering from primary pyodermas requiring topical antibiotic therapy without occlusive dressings.
- •>=6 years of age.
- •Written informed consent.
排除标准
- •Patients must not take any other antibiotics.
- •Patients should not be hypersensitive to any of the test drugs.
- •Patients are not to have any other investigational drug within one month of starting this study.
- •Patients cannot be enrolled more than once in the study.
- •Patients must not have any significant medical condition which, in the judgment of the investigator, might interfere with the study or require treatment.
- •Pregnant women and nursing mothers are to be excluded.
研究者
相似试验
已完成
4 期
Dalacin-T Gel Post Approval StudyAcne VulgarisNCT00219570Pfizer134
Unknown
3 期
Comparison of Nadifloxacin Cream Alone and With Benzoyl Peroxide Solution in the Treatment of AcneAcne VulgarisNCT00869492Marmara University90
已完成
不适用
Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel SyndromeConstipation-predominant Irritable Bowel SyndromeNCT00945334Mark Pimentel, MD37
已完成
2 期
Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis ComplexFacial AngiofibromaTuberous SclerosisNCT03826628Dermatology Specialties Limited Partnership107
已完成
3 期
ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis BullosaEpidermolysis BullosaNCT02384460Scioderm, Inc.169